A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures

Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men

(2013) Patrick Haentjens   ANNALS OF INTERNAL MEDICINE

Cost-Effectiveness of Different Screening Strategies for Osteoporosis in Postmenopausal Women

(2013) Smita Nayak et al.   ANNALS OF INTERNAL MEDICINE

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

(2012) Daniel R Murphy et al.   BMC MUSCULOSKELETAL DISORDERS

Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX™ thresholds for decision

(2012) Kazem Alzahouri et al.   JOINT BONE SPINE

The Clinical and Economic Burden of Poor Adherence and Persistence with Osteoporosis Medications in Ireland

(2012) Mickaël Hiligsmann et al.   VALUE IN HEALTH

Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France

(2011) François-Emery Cotté et al.   BMC HEALTH SERVICES RESEARCH

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

(2011) Socrates Papapoulos et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium

(2011) Mickaël Hiligsmann et al.   PHARMACOECONOMICS

The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands

(2011) R. Akehurst et al.   JOURNAL OF MEDICAL ECONOMICS

Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women

(2010) Mickaël Hiligsmann et al.   BONE

FRAX® and its applications in health economics—Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example

(2010) O. Ström et al.   BONE

The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients

(2010) Mickaël Hiligsmann et al.   HEALTH POLICY

Sources of interracial variation in bone mineral density

(2010) Tim Cundy et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective

(2010) F. Borgström et al.   OSTEOPOROSIS INTERNATIONAL

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

(2010) B. Jönsson et al.   OSTEOPOROSIS INTERNATIONAL

Direct and Indirect Costs of Non-Vertebral Fracture Patients with Osteoporosis in the US

(2010) Crystal Pike et al.   PHARMACOECONOMICS

Cost–Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication Adherence

(2010) Mickaël Hiligsmann et al.   VALUE IN HEALTH

Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective

(2010) Jean-Blaise Wasserfallen et al.   JOURNAL OF MEDICAL ECONOMICS

Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis

(2010) Fredrik Borgström et al.   JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years

(2009) Mickaël Hiligsmann et al.   BONE

Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women

(2009) Dana Bliuc   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®

(2009) F. Borgström et al.   OSTEOPOROSIS INTERNATIONAL

Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women

(2009) M. Hiligsmann et al.   OSTEOPOROSIS INTERNATIONAL

Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis

(2009) Mickaël Hiligsmann et al.   VALUE IN HEALTH

The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness Analysis

(2009) Melissa Thompson et al.   VALUE IN HEALTH

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

Cost-Effectiveness of Preventing Hip Fractures by Hip Protectors in Elderly Institutionalized Residents in Germany

(2008) Afschin Gandjour et al.   VALUE IN HEALTH

Belgian Methodological Guidelines for Pharmacoeconomic Evaluations: Toward Standardization of Drug Reimbursement Requests

(2008) Irina Cleemput et al.   VALUE IN HEALTH

An Economic Evaluation of Quantitative Ultrasonometry as Pre-Screening Test for the Identification of Patients with Osteoporosis

(2008) Mickaël Hiligsmann et al.   Disease management & health outcomes.

The cost-effectiveness of alendronate in the management of osteoporosis

(2007) John A. Kanis et al.   BONE

The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis

(2007) Hansheng Ding et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Medication Compliance and Persistence: Terminology and Definitions

(2007) Joyce A. Cramer et al.   VALUE IN HEALTH

Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis

(2006) Carolyn M. Klotzbuecher et al.   JOURNAL OF BONE AND MINERAL RESEARCH